Fig. 5

CD7 CAR-T cells exhibit remarkable antileukaemic effects in a leukaemia mouse model A Diagram of mouse model construction, CAR-T-cell treatment, and observation timeline. NTG mice received GFP-FFLuc-expressing MOLM-13 cells. After 5 days, different groups of mice received a single intravenous injection of vehicle (DPBS), NTR, or CD7 CAR-T cells, and tumour progression was continuously monitored. B GFP-FFLuc-expressing MOLM-13 cells were detected by flow cytometry before infusion. C Kinetics of leukaemia progression in individual mice receiving vehicle, NTR or CD7 CAR-T cells by IVIS imaging (n = 5). D IVIS images of individual mice showing the progression of leukaemia in the various groups (n = 5). ns, not significant; ****P < 0.0001